Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04028167 · ClinicalTrials.gov registry record · Phase 2

Induction FLOT With CROSS CRT for Esophageal Cancer

A Phase 2 study of Adenocarcinoma of the Gastroesophageal Junction and Adenocarcinoma Esophagus, sponsored by University of Colorado, Denver.

Active
Registry status
Phase 2
Development phase
40
Enrollment target
7
Study locations

NCT04028167: Active Phase 2 study of Adenocarcinoma of the Gastroesophageal Junction and Adenocarcinoma Esophagus, sponsored by University of Colorado, Denver.

NCT04028167 is a Phase 2 study of Adenocarcinoma of the Gastroesophageal Junction and Adenocarcinoma Esophagus that is active but no longer recruiting, run by University of Colorado, Denver. The registered enrollment target is 40 participants, below the 87-participant average among 7 other Adenocarcinoma of the Gastroesophageal Junction trials with a reported enrollment target (54% lower). The trial reports 7 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04028167, a Phase 2 study of Adenocarcinoma of the Gastroesophageal Junction and Adenocarcinoma Esophagus, is active but no longer recruiting, sponsored by University of Colorado, Denver.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
40 participants
Enrollment target
7
Study locations

Study Summary

This study evaluates a novel regimen of induction chemotherapy using a combination of docetaxel, oxaliplatin, and leucovorin, with short term infusional 5-FU (FLOT), given prior to chemoradiotherapy with concurrent carboplatin and paclitaxel, as neoadjuvant therapy prior to definitive surgical resection for patients with adenocarcinoma of the esophagus or gastroesophageal junction

Primary Outcome

The percentage of pathologic complete response at resection for patients who has completed the study regimen of induction FLOT, CROSS regimen chemoradiation, and surgical resection

Interventions

  • DRUG Sequential FLOT followed by chemoradiation

Study Locations (7)

Colorado

  • University of Colorado Hospital - Aurora
  • UCHealth Southern Colorado - Memorial Hospital Central - Colorado Springs
  • UCHealth Southern Colorado - Memorial Hospital North - Colorado Springs
  • UCHealth Northern Colorado - Poudre Valley Hospital - Fort Collins
  • UCHealth Northern Colorado - Harmony Campus - Fort Collins
  • UCHealth Northern Colorado - Greeley Hospital - Greeley
  • UCHealth Northern Colorado Medical Center of the Rockies - Loveland

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2020-04-08
Est. Completion 2027-04-19
Phase Phase 2
University of Colorado, Denver

1,283 total trials

What the registry record for NCT04028167 still lists

NCT04028167 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 87-participant average among 7 other Adenocarcinoma of the Gastroesophageal Junction trials with a reported enrollment target (54% lower).

The record links to 2 conditions, with Adenocarcinoma of the Gastroesophageal Junction appearing as the primary indexed condition, and to 1 intervention - of which Sequential FLOT followed by chemoradiation is the first listed.

NCT04028167 lists 7 locations in 1 state (Colorado).

Frequently Asked Questions

What is clinical trial NCT04028167 about?

NCT04028167 is a clinical study titled "Induction FLOT With CROSS CRT for Esophageal Cancer". This study evaluates a novel regimen of induction chemotherapy using a combination of docetaxel, oxaliplatin, and leucovorin, with short term infusional 5-FU (FLOT), given prior to chemoradiotherapy with concurrent carboplatin and paclitaxel, as neoadjuvant therapy prior to definitive surgical resec...

What is the current status of trial NCT04028167?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2020-04-08. Estimated completion is 2027-04-19.

What conditions does trial NCT04028167 study?

This clinical trial studies the following conditions: Adenocarcinoma of the Gastroesophageal Junction, Adenocarcinoma Esophagus.

What interventions are being tested in trial NCT04028167?

The interventions under investigation include: Sequential FLOT followed by chemoradiation (DRUG).

Who is sponsoring clinical trial NCT04028167?

This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04028167 being conducted?

This trial has 7 study locations across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Adenocarcinoma of the Gastroesophageal Junction

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01306019 · 40 participants · Phase 1

    Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)

  • NCT01608152 · 40 participants

    Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors

  • NCT01668082 · 40 participants · NA

    An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection

  • NCT02015013 · 40 participants · Phase 2

    Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04028167, the US trial registry maintained by the National Library of Medicine. NCT04028167 (small enrollment · multi site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.